New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC (KARD) vs Nektar Therapeutics (NKTR)

KARDIGAN INC and Nektar Therapeutics are both Biotechnology companies. KARDIGAN INC and Nektar Therapeutics are of similar size ($1.2B and $1.1B). Across the 9 metrics below, Nektar Therapeutics leads on 6 and KARDIGAN INC on 3.

Valuation

Metric KARD NKTR Biotechnology median
P/E n/m n/m 8.49
P/S — 19.79 8.56
P/B 1.86 1.22 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales — 8.01 8.00
Earnings yield (115.30%) (21.38%) (35.81%)
Free cash flow yield (21.31%) (24.94%) (25.41%)

Profitability

Metric KARD NKTR Biotechnology median
Gross margin — 100.00% 70.18%
Operating margin — (319.75%) 0.00%
Net margin — (339.67%) 0.00%
Free cash flow margin — (493.41%) 0.00%
Return on equity (117.38%) (37.92%) (51.58%)
Return on assets (80.59%) (26.48%) (45.91%)
Return on invested capital (187.24%) (44.31%) 0.00%

Growth

Metric KARD NKTR Biotechnology median
Revenue growth (TTM) — (16.64%) 7.20%
EPS growth (last fiscal year) (68.79%) (11.89%) 29.04%
Revenue growth, 5-year CAGR — (18.43%) 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric KARD NKTR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.62 9.00 4.79
Net debt to EBITDA 1.70 1.77 1.01

Dividend

Metric KARD NKTR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KARD NKTR Biotechnology median
Market cap 1.17b 1.11b 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack